key: cord-0977158-cgchmys1
authors: Clancy, Cornelius J; Nguyen, M Hong
title: COVID-19, superinfections and antimicrobial development: What can we expect?
date: 2020-05-01
journal: Clin Infect Dis
DOI: 10.1093/cid/ciaa524
sha: ac23c726984507f6a7df84631fbed6ec1877f4da
doc_id: 977158
cord_uid: cgchmys1

Coronavirus disease 2019 (COVID-19) arose at a time of great concern about antimicrobial resistance (AMR). No studies have specifically assessed COVID-19-associated superinfections or AMR. Based on limited data from case series, it is reasonable to anticipate that an appreciable minority of patients with severe COVID-19 will develop superinfections, most commonly pneumonia due to nosocomial bacteria and Aspergillus. Microbiology and AMR patterns are likely to reflect institutional ecology. Broad-spectrum antimicrobial use is likely to be widespread among hospitalized patients, both as directed and empiric therapy. Stewardship will have a crucial role in limiting unnecessary antimicrobial use and AMR. Congressional COVID-19 relief bills are considering antimicrobial reimbursement reforms and antimicrobial subscription models, but it is unclear if these will be included in final legislation. Prospective studies on COVID-19 superinfections are needed, data from which can inform rational antimicrobial treatment and stewardship strategies, and models for market reform and sustainable drug development.

A c c e p t e d M a n u s c r i p t 5 In this article, we review the limited published data on bacterial and fungal infections among COVID-19 patients, and offer perspectives on what to expect with superinfections, AMR and antimicrobial development during the pandemic.

As of this writing, no studies have specifically investigated COVID-19 superinfections.

Superinfections and antimicrobial (antibacterial, antifungal) usage are presented in a few sentences or within tables of papers, without mention of diagnostic criteria or case definitions. Information from retrospective reports published through April 21, 2020 is summarized in Table 1 .

Secondary infections were reported in 5%-27% of SARS-CoV-2-infected adults in several hospitals in Wuhan, China through mid-February 2020, including 50%-100% of those who died. [13] [14] [15] [16] [17] [18] [19] Secondary infections were identified in 13.5%-44% of intensive care unit (ICU) patients with COVID-19. [15, 19, 20] The most common type of infection among ICU patients was bacterial or fungal pneumonia; bloodstream and urinary tract infections were also noted.

Organisms cultured from patients included pan-drug resistant (PDR)-Acinetobacter baumannii, Klebsiella pneumoniae carbapenemase (KPC)-producing K.

pneumoniae, extended spectrum beta lactamase (ESBL)-producing K. pneumoniae, ESBLproducing Pseudomonas aeruginosa, Enterobacter cloacae, Serratia marcescens, Aspergillus fumigatus, Aspergillus flavus, Candida albicans and Candida glabrata. [14, 18, 20, 21] Median times to ICU admission and onset of secondary infection among patients at 2 hospitals were 10-12 days and 17 days after first COVID-19 symptoms, respectively. [16, 17] Median time to death was 19 days, suggesting that superinfections were often terminal events. In March 2020 at 2 New York City hospitals, bacteremia was found in 6% and 12% of all COVID-19 patients and mechanically ventilated patients, respectively. [22] In the first A c c e p t e d M a n u s c r i p t 6 European series, one of three patients with severe COVID-19 in France was diagnosed with secondary A. baumannii and A. flavus co-infection. [23] In a report from 552 hospitals in 30 Chinese provinces, 58% of patients were treated with antibiotics [17] . Antibiotics and antifungals were administered to 80%-100% and 7.5%-15% of critically ill COVID-19 patients in Chinese ICUs, respectively. [13-16, 21, 24, 25] At several Wuhan hospitals, fluoroquinolones, cephalosporins, carbapenems, azithromycin, vancomycin and linezolid were most common empiric agents, but details on dosing and treatment courses were lacking. [13, 14, 21, 25, 26] Empiric antimicrobial usage was likely widespread because 25%-70% of severely ill COVID-19 patients manifested evidence of sepsis, and it was very difficult to exclude bacterial or fungal superinfections based on signs and symptoms, physical findings, radiographic abnormalities and laboratory results. [16] [17] [18] The French patient with severe COVID-19 and aspergillosis was treated with various combinations of meropenem, tigecycline, levofloxacin, aerosolized colistimethate, voriconazole and/or isavuconazole before dying. [23] In contrast to the data above, studies of COVID-19 in 788 hospitalized patients in Zhejiang province, China and 24 patients in Seattle ICUs in January-February 2020 reported that there were no superinfections. [27, 28] In a paper on 21 critically ill COVID-19 patients at a Kirkland, Washington hospital, one P. auruginosa bloodstream infection was noted. [29] Other COVID-19 cases series did not report information on superinfections. [26, 30] Washington. [20, 22, 25, 26, 29, 30] Second, severe COVID-19 is associated with immune dysregulation, which may create a milieu for bacterial or fungal proliferation. [16, 32, 33] Patients with severe COVID-19 have higher pro-inflammatory (e.g., interleukin-2, soluble interleukin-2 receptor, interleukin-6, tumor necrosis factor-alpha) and anti-inflammatory cytokine (e.g., interleukin-4, interleukin-10) levels, fewer CD4 and CD8 cells, and less interferon-gamma expression by CD4 cells than those with more moderate disease, which likely contributes to lung pathology. [32, 33] Cytokine release syndrome, immune exhaustion and/or lung damage may pre-dispose to superinfection.

Present uncertainties about COVID-19 superinfections will be resolved as the pandemic unfolds and greater time and resources are available to publish detailed data based on rigorous case definitions. Bacterial or fungal co-infections are unlikely to be common in patients with mild COVID-19 or in those with more serious disease upon admission to the hospital. It is reasonable to anticipate that superinfections will occur in an appreciable minority of critically ill, hospitalized patients, since risk factors for nosocomial infections such as advanced age, underlying systemic diseases, mechanical ventilation, and prolonged hospital and ICU stays are prominent features of severe disease. [14, 26] Susceptibility to infections may be abetted by immune dysregulation coinciding with acute respiratory distress. The use of corticosteroids, tocilizumab (anti-interleukin-6 monoclonal antibody) or other immunomodulatory agents for treatment of COVID-19 could have unintended consequences for secondary infections. Adherence to rigorous infection prevention practices will be crucial in limiting nosocomial infections.

Bacterial and fungal pneumonias, especially ventilator-associated pneumonias, will likely be the most common superinfections; patients will also be susceptible to bloodstream and urinary tract infections. Microbiology and AMR patterns are likely to be consistent with would codify and extend CMS reforms by carving out designated antimicrobials from the DRG, and reimbursing hospitals for use of these drugs at or slightly above cost. [45] A c c e p t e d M a n u s c r i p t 11 DISARM sets stewardship criteria for hospitals, and mandates reporting of data on antimicrobial use. For both CMS reforms and DISARM, reimbursement is still linked to perunit drug use, which creates tension between tying revenue to prescription volume and responsible stewardship. Moreover, these reforms do not address the biggest challenge in the market, which is that numbers of AMR infections requiring a new drug are currently insufficient in the US to support more than a few agents. For example, we estimated that the annual US market for new anti-CRE drugs is only ~$300 million, even with full reimbursement. [10, 45] Other models propose to de-link revenue from use, thereby attempting to compensate the societal or insurance value of antibiotics against AMR pathogens. [12] De-linkage models are often described using a fire extinguisher analogy:

you pay for a fire extinguisher in case you need it, rather than trying to find or manufacture one after a fire starts. [9, 46] The costs of these models are paid up-front, which may present challenges in securing funding.

An alternative model proposes that a non-profit entity or entities, funded by government and/or foundation seed grants, replace or operate alongside entrepreneurial companies. [47] Reducing the need to maximize revenue may lower drug costs. A non-profit model would be less able to leverage financial resources of investment markets, which would almost certainly mean fewer products reaching clinic and may lessen innovation. A counterargument is that there are already too many drugs in certain spaces, such as anti-CRE and anti-methicillin resistant S. aureus agents. Non-profits have developed tuberculosis and malaria drugs, but their ability to sustain a successful pipeline against multiple pathogens and to respond to newly emergent threats is unproven. In addition to drug discovery and development expenses, non-profits that brought a new agent to market themselves would face formidable post-approval costs for manufacturing, regulatory compliance and pharmacovigilance (at least $350 million over the first ten years). [48] Failure to enact antimicrobial reimbursement reforms may lead to a non-profit model by default.

A c c e p t e d M a n u s c r i p t 12

Medical and economic devastation wrought by COVID-19 has drawn much-needed At least one other large COVID-19 relief bill will likely be considered by Congress.

Groups endorsing antibiotic reform are advocating for DISARM or an antibiotic subscription model, along the lines of programs being piloted in the United Kingdom and Sweden. [9, 46] Details of the PASTEUR (Pioneering Antimicrobial Subscriptions to End Upsurging Resistance) Act were being finalized as this manuscript was written. Since subscription models propose that government pays companies a fee to ensure unfettered access to specified antibiotics in event of need, the legislation may fit within broader calls for investment in infectious diseases and public health preparedness in the aftermath of COVID- If DISARM or PASTEUR are not included in comprehensive COVID-19 response legislation, the issues of AMR and antimicrobial development will likely not be considered again until the new Congress in 2021. In the interim, legislative priorities will be impacted by the course of COVID-19 and November 2020 elections. Another year without some reform to the marketplace will undoubtedly lead to more companies failing, and to further chilling of investor enthusiasm for new antibiotic development. As time passes, more drastic measures may be needed to salvage antibiotic development even as AMR increases.

As the COVID-19 pandemic proceeds, prospective studies are needed to systematically collect epidemiologic, clinical, microbiologic and AMR data on superinfections. 

Fully delinked MER [43] Direct prize awarded to companies that introduce a priority antimicrobial, which can be given as series of payments and serve as main revenue stream.

Provides predictable revenue to companies. Units sold at contractually agreed-upon price with conditions on stewardship, access, transparency.

Necessary payments likely to be >$1B per drug.

Financially unsustainable without accompanying method of revenue generation, such as tax on existing generics.

Partially delinked MER [43] Direct prize with smaller awards than fully delinked model, designed to augment revenue especially as antimicrobial establishes market.

Provides predictable revenue to companies. Can work within existing reimbursement models. Market disruptions are lower than fully de-linked MER or exclusivity voucher models. Can still have conditions attached.

Companies will need to generate sustainable revenue stream based on unit sales.

Preparing for the next pandemic

The Infectious Diseases Society of America's 10 x '20 Initiative (10 New Systemic Antibacterial Agents US Food and Drug Administration Approved by 2020): Is 20 x '20 a Possibility?

Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness

Aspergillus fumigatus morphology and dynamic host interactions

Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study

Multidrug-Resistant Bacterial Infections in U.S. Hospitalized Patients

Antimicrobial Resistance Threats in the United States

Tackling drug-resistant infections globally: Final report and recommendations

Tetraphase Sold For $14m … And $600m Goes Up In Smoke! Antimicrobial Resistance Solutions blog

Estimating the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in the United States Using Antibiotic Prescription Data

Combating resistance while maintaining innovation: the future of antimicrobial stewardship

Antibiotic Development Incentives That Reflect Societal Value of Antibiotics

Clinical Features and Short-term Outcomes of 102 Patients with Corona Virus Disease

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Eleven faces of coronavirus disease 2019

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Clinical Features of 69 Cases with Coronavirus Disease

Clinical Characteristics of Covid-19 in New York City

Clinical and virological data of the first cases of COVID-19 in Europe: a case series

Clinical Characteristics of Coronavirus Disease 2019 in China

Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan: A Retrospective Observational Study

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

Covid-19 in Critically Ill Patients in the Seattle Region -Case Series

Analysis of Epidemiological and Clinical features in older patients with Corona Virus Disease 2019 (COVID-19) out of Wuhan

Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State

Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA 2020. 31. Prevention CfDCa. Coronavirus Disease 2019: Infection Control Guidance

Clinical and immunologic features in severe and moderate Coronavirus Disease

SARS-CoV-2: A Storm is Raging

Lawmakers, experts warn of U.S. reliance on foreign-made drugs, medical products

Carbapenem-Resistant Acinetobacter baumannii and Enterobacteriaceae in South and Southeast Asia

Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America

Trends in antimicrobial drug development: implications for the future

Administration USFaD. Novel Drug Approvals

Antibiotic and Antifungal Update

2019 antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline

Critical analysis of antibacterial agents in clinical development

Novel Utility, & The Illusion Of Skill: What To Develop? What To Reward?

Pull Incentives for Antibacterial Drug Development: An Analysis by the Transatlantic Task Force on Antimicrobial Resistance

Transferrable Market Exclusivity Extensions to Promote Antibiotic Development: An Economic Analysis

Estimating the size of the United States market for new antibiotics with activity against carbapenem-resistant Enterobacteriaceae

New Mechanisms for Antibiotic Reimbursement in the United States: CMS's IPPS FY2020 Final Rule

Sustainable Discovery and Development of Antibiotics -Is a Nonprofit Approach the Future?

Part 2 / Bankruptcy Is Not The End / Post-Approval Costs For An Antibiotic. Antimicrobial Resistance Solutions blog

A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t 19 characterized Chen T 2 [14] Wuhan, 1 hospital 274 3